Everything below concerns Alpha-MSH. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
== Early life == Flay was born on December 10, 1964, in New York City, to Bill and Dorothy Barbara (McGuirk) Flay. He was raised on the Upper East Side of Manhattan. He is a fourth-generation Irish American and was raised Catholic, attending denominational schools. At age 8, Flay asked for an Easy-Bake Oven for Christmas. His father thought that a G.I. Joe would be more appropriate. Despite his father's objections, he received them both.
Schymanski has developed a subset of PubChem for exposomics, PubChemLite, which can be annotated to increase ability of researchers to identify unknown environmental compounds. Within this field, Schymanski is working to automate the identification of a group of fluorinated compounds called ‘per- and poly-fluoroalkyl substances’ (PFASs) in order to increase the ability of researchers to find unknown PFAS in the environment. Schymanski is an advocate for open science and data sharing. Within the NORMAN network, a collaborative activity across Europe, North America, and Asia, Schymanski worked in 2011 with the team that established NORMAN MassBank, which was a community-driven project to gather information about small molecules. In 2015, Schymanski expanded this type of data with the NORMAN Suspect List Exchange. Schymanski has also worked to develop computational tools that allow the processing of complex high resolution mass spectrometry data and sought to establish standards to consider the quality of the mass spectrometry data. Schymanski's 2014 publication in Environmental Science & Technology establishes a means to estimate confidence in the quality of unknown organic compound identifications (now known as "Schymanski Confidence") and, as of 2021, has over 1000 citations. In 2018, Schymanski considered this paper her greatest achievement because it established the standard for compound identification in metabolomics and encouraged community conversation about future of these tools.
== Clinical significance == Chromosomal rearrangements and altered expression of this gene have been implicated in several neurological, neoplastic, and other types of diseases, including Alzheimer's disease, Down syndrome, epilepsy, amyotrophic lateral sclerosis, schwannoma, melanoma, and type I diabetes mellitus. It has been suggested that the regulation of S100B by melittin has potential for the treatment of epilepsy.
=== Committee assignments === Committee on Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Subcommittee on Commerce, Justice, Science, and Related Agencies Subcommittee on Energy and Water Development Subcommittee on Financial Services and General Government Committee on Banking, Housing, and Urban Affairs Subcommittee on Economic Policy Subcommittee on Financial Institutions and Consumer Protection Subcommittee on Housing, Transportation, and Community Development Committee on the Budget Committee on the Judiciary Subcommittee on Border Security and Immigration Subcommittee on Crime and Terrorism Subcommittee on Privacy, Technology and the Law Subcommittee on Intellectual Property Committee on Small Business and Entrepreneurship
Congenital errors of amino acid metabolism are inherited metabolic disorders that impair the synthesis and degradation of amino acids. This means that the body has trouble breaking down and building some amino acids, the building blocks of protein in the body. The body can also have trouble with cellular update up amino acids. There are many different disorders in this classification and it can manifest in different ways. Many of these disorders result in the buildup of amino acids in the body which can be harmful and sometimes life threatening. Many of these disorders are part of newborn screening blood tests to ensure an early diagnosis and appropriate treatment for best possible outcomes.
Sources: en.wikipedia.org
Deep, superficial, and perforator veins The three main compartments of the venous system are the deep veins, the superficial veins, and the perforator veins. Superficial veins are those closer to the surface of the body, and have no corresponding arteries. Deep veins are deeper in the body and have corresponding arteries. Perforator veins drain from the superficial to the deep veins. These are usually referred to in the lower limbs and feet. Superficial veins include the very small spider veins of between 0.5 and 1 mm diameter, and reticular or feeder veins.
Zearalenone (ZEN), also known as RAL and F-2 mycotoxin, is a potent estrogenic metabolite produced by some Fusarium and Gibberella species. Specifically, the Gibberella zeae, the fungal species where zearalenone was initially detected, in its asexual/anamorph stage is known as Fusarium graminearum. Several Fusarium species produce toxic substances of considerable concern to livestock and poultry producers, namely deoxynivalenol, T-2 toxin, HT-2 toxin, diacetoxyscirpenol (DAS) and zearalenone. Particularly, ZEN is produced by Fusarium graminearum, Fusarium culmorum, Fusarium cerealis, Fusarium equiseti, Fusarium verticillioides, and Fusarium incarnatum. Zearalenone is the primary toxin that binds to estrogen receptors, causing infertility, abortion or other breeding problems, especially in swine. Often, ZEN is detected together with deoxynivalenol in contaminated samples and its toxicity needs to be considered in combination with the presence of other toxins. Zearalenone is heat-stable and is found worldwide in a number of cereal crops, such as maize, barley, oats, wheat, rice, and sorghum. Its production increases when the climate is warm with air humidity at or above twenty percent. The environmental pH plays also a role in the toxin's production. When temperatures fall to 15 °C, alkaline soils still support ZEN production. At the preferred Fusarium temperature, which ranges between 25 °C and 30 °C, neutral pH results in the greatest toxin production.
29-30 January An ambush patrol of Company C, 1st Battalion, 7th Marines observed approximately 300 PAVN cross the Song Ky Lam River, 6 km west of Điện Bàn. The company called in artillery fire and then engaged the unit, with Company D, 5th Marines joining the action. A search of the area at dawn found 72 PAVN dead. The first M551 Sheridan Armored Reconnaissance Vehicles arrived in South Vietnam and were deployed by the 3rd Squadron, 4th Cavalry Regiment and the 1st Squadron, 11th Armored Cavalry Regiment.
Any condition that results in the production of abnormal hemoglobin is included under the broad category of hemoglobinopathies. Worldwide, it is estimated that 7% of the population may carry a hemoglobinopathy with clinical significance. The most well known condition in this group is sickle cell disease. Newborn screening for a large number of hemoglobinopathies is done by detecting abnormal patterns using isoelectric focusing, which can detect many different types of abnormal hemoglobins. In the United States, newborn screening for sickle cell disease was recommended for all infants in 1987, however it was not implemented in all 50 states until 2006. Early identification of individuals with sickle cell disease and other hemoglobinopathies allows treatment to be initiated in a timely fashion. Penicillin has been used in children with sickle cell disease, and blood transfusions are used for patients identified with severe thalassemia.
Alistair Barkley who goes on the run with Eddie when they are framed for Alistair's murder and the destruction of his laboratory Fred Ward as FBI Agent Leon Ford, who leads the investigation to discover the cause of the destruction of the laboratory; initially focusing on Eddie and Lily, he soon suspects the involvement of government organizations Kevin Dunn as FBI Agent Doyle, Ford's assistant in the investigation who helps Ford track down Eddie, Lily, and later, C-Systems Brian Cox as Lyman Earl Collier, Chairman of C-Systems Research who is behind the conspiracy to keep the hydrogen power plant a secret Joanna Cassidy as Maggie McDermott, an old friend of Eddie's who lives in an observatory in Wisconsin, where Eddie and Lily escape to after a warrant is issued for their arrest Chelcie Ross as FBI Agent Ed Rafferty Nicholas Rudall as Dr. Alistair Barkley, head of the project to develop energy from the water who is later suffocated Tzi Ma as Lu Chen, Project Manager on the Hydrogen Project and Dr. Barkley's right-hand man; when Barkley is killed, Dr. Chen is kidnapped and forced to work at C-Systems Krzysztof Pieczyński as Lucasz Screbneski, the scientist on the original project who is secretly working for C-Systems Eddie Bo Smith Jr. and Danny Goldring as Yusef Reed and Clancy Butler, Collier's right hand men for C-Systems Margaret Travolta as Anita Fermi, Shannon's personal assistant. In addition, Michael Shannon and Neil Flynn make appearances as a van driver and a Wisconsin State Police Trooper, respectively.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.